publication date: Jun. 10, 2016

In Brief

Former NCI Director Broder to Retire from Intrexon

 

SAMUEL BRODER announced he plans to retire as senior vice president and head of the health sector of Intrexon Corp.

Broder has served in various leadership capacities at Intrexon, including as chairman of the health sector and executive vice [resident of scientific and public affairs, and will continue as a consultant to the company.

“Heading the health sector for Intrexon has been the capstone of my career. I will miss working every day with the brilliant staff at Intrexon, yet eagerly anticipate seeing their collective efforts unfold in bringing new therapeutics to market,” said Broder.

Broder’s previously held leadership roles in both industry and academia, including as executive vice president and chief medical officer at Celera Corp. and senior vice president of research and development at IVAX Corp., as well as director of the NCI for six years.

“Sam’s contributions to the field of medicine have been instrumental in advancing new therapies to treat many diseases, in particular cancer and AIDS, and his tireless work and efforts have had a significant impact on the lives of many patients,” said Intrexon President Geno Germano. “He leaves Intrexon and its current and future collaborators in a strong position to continue that success. While I am evaluating numerous candidates to head our Health Sector, I am pleased that we shall continue to enjoy Sam’s assistance.”

 

YOSHINORI OHSUMI was awarded the … Continue reading 42-23 Former NCI Director Broder To Retire from Intrexon Corp.

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.